


SUPPLEMENTARY FIGURES



Supplementary Figure 1. (A) The heat map of 9 IncRNAs expression in the test. (B) Exhibition of necroptosis-related IncRNAs model based on risk score of the test. (C) Survival time and survival status between low- and high-risk groups in the test. (D) The heat map of 9 IncRNAs expression in the train. (E) Exhibition of necroptosis-related IncRNAs model based on risk score of the train. (F) Survival time and survival status between low- and high-risk groups in the train.



Supplementary Figure 2. (1–25) 25 immunotherapeutic drugs showed a significant IC₅₀ difference in different risk groups (all p<0.05).



Supplementary Figure 3. (1–29) 29 immunotherapeutic drugs showed a significant IC₅₀ difference in different clusters (all p<0.05).